시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 포유류 세포 발효 기술 시장 보고서(2025년)
Mammalian Cell Fermentation Technology Global Market Report 2025
상품코드 : 1825796
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,469,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,350,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,232,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

포유류 세포 발효 기술 시장 규모는 향후 몇 년 동안 급성장할 것으로 예상됩니다. 2029년에는 CAGR 11.0%로 870억 7,000만 달러로 성장할 것입니다. 예측 기간의 성장은 만성질환 유병률 증가, 다국적 기업의 투자 증가, 만성질환 빈도 증가, 첨단 바이오 공정 기술 채택 증가, 신규 재조합 단백질 연구개발 투자 증가, 암 치료에 대한 수요 증가 등에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 세포배양 기술 발전, 바이오리액터 설계 기술 발전, 차세대 바이오 공정 기술 개발, 멀티오믹스 접근법 통합, 기술 주도형 자동화 등이 있습니다.

향후 5년간 11.0%의 성장률 전망은 지난번 전망치보다 0.7% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 무역 마찰은 독일과 네덜란드에서 개발된 바이오리액터 시스템 및 배양액 가격을 급등시켜 의약품 제조 지연과 바이오의약품 연구개발(R&D) 비용 상승을 초래하여 미국의 바이오의약품 제조 도입을 저해할 수 있습니다. 또한, 상호 관세와 무역 마찰 및 제한 강화로 인한 세계 경제 및 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

생물학적 제제에 대한 수요 증가는 향후 포유류 세포 발효 기술 시장의 성장을 견인할 것으로 예상됩니다. 생물학적 제제는 생물 또는 그 구성요소에서 유래한 의약품으로 암, 자가면역질환, 감염성 질환 등의 질병 치료에 사용되는 경우가 많습니다. 생물학적 제제에 대한 수요 증가는 생명공학 기술의 발전, 만성질환 치료 효과, 규제 당국의 승인, 연구개발 투자 증가에 기인합니다. 포유류 세포 발효 기술은 복잡한 생물학적 제제를 생산하고 맞춤형 표적 치료제에 대한 수요 증가에 대응하기 위해 매우 중요합니다. 확장성, 다용도성, 고품질 단백질 생산능력은 바이오 제약 산업의 혁신을 촉진할 수 있습니다. 예를 들어, 국립의학도서관은 2024년 2월 미국 식품의약국(FDA)이 2023년 승인한 신약은 55개 품목으로, 이 중 29개 품목은 신규 화학제품(NCE), 25개 품목은 신규 생물학적 제제(NBE)로 2022년 37개 품목에 비해 50% 증가했다고 보고했습니다. 따라서 생물학적 제제에 대한 수요 증가는 포유류 세포 발효 기술 시장의 확대를 주도하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSM
영문 목차

영문목차

Mammalian cell fermentation technology refers to the process of cultivating mammalian cells under controlled conditions to produce biopharmaceuticals, vaccines, or other biological products. This technology involves optimizing cell growth and protein expression in bioreactors or fermenters, ensuring the production of high-quality and consistent yields of desired therapeutic proteins or substances.

The main types of mammalian cell fermentation technology include Chinese hamster ovary (CHO) cell fermentation, human embryonic kidney (HEK) cell fermentation, baby hamster kidney (BHK) cell fermentation, murine myeloma cell fermentation, and other types. Chinese hamster ovary (CHO) cell fermentation is a biotechnological process used in the production of therapeutic proteins, such as monoclonal antibodies and recombinant proteins. The various applications of mammalian cell fermentation technology include monoclonal antibodies, recombinant proteins, vaccines, hormones, enzymes, and other products. The end-users of this technology include biopharmaceutical companies, contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and academic and research institutes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The mammalian cell fermentation technology market research report is one of a series of new reports from The Business Research Company that provides mammalian cell fermentation technology market statistics, including mammalian cell fermentation technology industry global market size, regional shares, competitors with a mammalian cell fermentation technology market share, detailed mammalian cell fermentation technology market segments, market trends, and opportunities, and any further data you may need to thrive in the mammalian cell fermentation technology industry. This mammalian cell fermentation technology research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The mammalian cell fermentation technology market size has grown rapidly in recent years. It will grow from $51.29 billion in 2024 to $57.37 billion in 2025 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to increased demand for biologics and biosimilars, increased focus on personalized medicine, increased output of biopharmaceuticals, and increased demand for scalable and effective cell culture methods.

The mammalian cell fermentation technology market size is expected to see rapid growth in the next few years. It will grow to $87.07 billion in 2029 at a compound annual growth rate (CAGR) of 11.0%. The growth in the forecast period can be attributed to the increasing prevalence of chronic diseases, rising investments by multinational corporations, rising frequency of chronic diseases, increasing adoption of advanced bioprocessing techniques, increasing investment in research and development of novel recombinant proteins and growing demand for cancer therapies. Major trends in the forecast period include technological advancements in cell culture, technological advancements in bioreactor design, developing next-generation bioprocessing technologies, integration of multi-omics approaches, and technology-driven automation.

The forecast of 11.0% growth over the next five years reflects a modest reduction of 0.7% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of biologics production by inflating prices of bioreactor systems and culture media developed in Germany and the Netherlands, resulting in slower drug manufacturing and higher biopharmaceutical research and development (R&D) costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing demand for biologics is anticipated to drive the growth of the mammalian cell fermentation technology market in the future. Biologics, which are medical products derived from living organisms or their components, are often used to treat diseases such as cancer, autoimmune disorders, and infectious diseases. The growing demand for biologics is driven by advancements in biotechnology, their effectiveness in treating prevalent chronic diseases, regulatory approvals, and increased investment in research and development. Mammalian cell fermentation technology is crucial for producing complex biologics, meeting the rising demand for personalized and targeted therapeutics. Its scalability, versatility, and ability to produce high-quality proteins foster innovation in the biopharmaceutical industry. For example, the National Library of Medicine reported in February 2024 that the Food and Drug Administration (FDA) approved 55 new drugs in 2023, including 29 new chemical entities (NCEs) and 25 new biological entities (NBEs), marking a 50% increase compared to the 37 approvals in 2022. Therefore, the growing demand for biologics is driving the expansion of the mammalian cell fermentation technology market.

Major companies in the mammalian cell fermentation technology market are focusing on developing innovative solutions, such as mammalian cell culture, to strengthen their market position. Mammalian cell culture is an essential tool in various fields, including biomanufacturing, research, and regenerative medicine, as it facilitates the production of therapeutic proteins, vaccines, and functional cells or tissue analogs. For example, in June 2024, Syntegon, a Germany-based biotechnology company, introduced its new Modular Bioprocessing Platform (MBP) at Achema 2024. This cutting-edge platform is designed to address key challenges in biopharmaceutical production. The MBP is a highly flexible, fully integrated, and automated solution capable of supporting a range of applications, including microbial and mammalian cell cultures, proteins, peptides, oligonucleotides, plasmid DNA, and recombinant vaccines. The modular design of the MBP allows for reduced lead times and costs while maintaining high functionality and quality, adhering to the rigorous "made in Germany" standard. Additionally, the platform's prefabricated cleanroom design places all peripheral technology outside the cleanroom, enhancing efficiency and simplifying maintenance, making it an advanced solution in the mammalian cell fermentation technology market.

In February 2024, Chrysea Limited, an Ireland-based biotechnology company, acquired Rodon Biologics from the Iberfar Group for an undisclosed amount. With this acquisition, Chrysea aims to strengthen its synthetic biology and biopharmaceutical development capabilities by integrating Rodon Biologics' expertise in protein engineering, cell-line development, precision fermentation, downstream processing, formulation, analytics, and production. Rodon Biologics, a Portugal-based manufacturer of biological products, operates in mammalian cell fermentation technology.

Major companies operating in the mammalian cell fermentation technology market are AbbVie Inc., Thermo Fisher Scientific Inc, AstraZeneca PLC, Roche Holdings Inc., Merck KGaA, AGC Group, Lonza Group Ltd., Boehringer Ingelheim GmbH, Catalent Inc., Sartorius AG, Samsung Biologics Co. Ltd., WuXi Biologics, Biocon Limited, Eppendorf AG, KBI Biopharma Inc., Fujifilm Diosynth Biotechnologies, Avid Bioservices Inc., BiOZEEN, Nordmark Pharma GmbH, Scorpius BioManufacturing Inc

North America was the largest region in the mammalian cell fermentation technology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mammalian cell fermentation technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the mammalian cell fermentation technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The mammalian cell fermentation technology market consists revenues earned by entities by providing services such as cell line development, process development, cell culture and fermentation, analytical and quality control services, and formulation and fill-finish services. The market value includes the value of related goods sold by the service provider or included within the service offering. The mammalian cell fermentation technology market also includes of sales of biosimilars, cell and gene therapy products, diagnostic enzymes and proteins, and therapeutic proteins. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Mammalian Cell Fermentation Technology Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on mammalian cell fermentation technology market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for mammalian cell fermentation technology ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The mammalian cell fermentation technology market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Mammalian Cell Fermentation Technology Market Characteristics

3. Mammalian Cell Fermentation Technology Market Trends And Strategies

4. Mammalian Cell Fermentation Technology Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Mammalian Cell Fermentation Technology Growth Analysis And Strategic Analysis Framework

6. Mammalian Cell Fermentation Technology Market Segmentation

7. Mammalian Cell Fermentation Technology Market Regional And Country Analysis

8. Asia-Pacific Mammalian Cell Fermentation Technology Market

9. China Mammalian Cell Fermentation Technology Market

10. India Mammalian Cell Fermentation Technology Market

11. Japan Mammalian Cell Fermentation Technology Market

12. Australia Mammalian Cell Fermentation Technology Market

13. Indonesia Mammalian Cell Fermentation Technology Market

14. South Korea Mammalian Cell Fermentation Technology Market

15. Western Europe Mammalian Cell Fermentation Technology Market

16. UK Mammalian Cell Fermentation Technology Market

17. Germany Mammalian Cell Fermentation Technology Market

18. France Mammalian Cell Fermentation Technology Market

19. Italy Mammalian Cell Fermentation Technology Market

20. Spain Mammalian Cell Fermentation Technology Market

21. Eastern Europe Mammalian Cell Fermentation Technology Market

22. Russia Mammalian Cell Fermentation Technology Market

23. North America Mammalian Cell Fermentation Technology Market

24. USA Mammalian Cell Fermentation Technology Market

25. Canada Mammalian Cell Fermentation Technology Market

26. South America Mammalian Cell Fermentation Technology Market

27. Brazil Mammalian Cell Fermentation Technology Market

28. Middle East Mammalian Cell Fermentation Technology Market

29. Africa Mammalian Cell Fermentation Technology Market

30. Mammalian Cell Fermentation Technology Market Competitive Landscape And Company Profiles

31. Mammalian Cell Fermentation Technology Market Other Major And Innovative Companies

32. Global Mammalian Cell Fermentation Technology Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Mammalian Cell Fermentation Technology Market

34. Recent Developments In The Mammalian Cell Fermentation Technology Market

35. Mammalian Cell Fermentation Technology Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기